On August 31, 2021, Treatment Action Group (TAG) and Black AIDS Institute (BAI) held a community discussion to get the latest updates on the impact of the Delta variant.
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020 seeking community perspectives on COVID-19 vaccine development.
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.
On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative.
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.
Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.